• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc.

    6/18/24 7:00:00 AM ET
    $BSX
    $SILK
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BSX alert in real time by email

    Acquisition adds innovative technology for stroke prevention to vascular portfolio

    MARLBOROUGH, Mass., June 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (NASDAQ:SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The purchase price is $27.50 per share, reflecting an enterprise value of approximately $1.16 billion.i

    Carotid artery disease is the cause of one-third of all strokes and a condition in which the carotid arteries in the neck become narrowed or blocked due to the buildup of plaque.ii Treatment options for this disease include medical therapy management, placement of a stent, or surgery to reduce the risk of stroke. The TCAR procedure involves accessing the carotid artery through a small incision in the neck and temporarily reversing blood flow away from the brain to prevent plaque from dislodging and causing a stroke. A stent is then placed at the site of the blockage for long-term plaque stabilization and future stroke prevention.

    "The TCAR platform developed by Silk Road Medical is a notable advancement in the field of vascular medicine, which has revolutionized stroke prevention and the treatment of carotid artery disease," said Cat Jennings, president, Vascular, Peripheral Interventions, Boston Scientific. "We believe the addition of this clinically differentiated technology to our vascular portfolio demonstrates our continued commitment to provide meaningful innovation for physicians who care for patients with peripheral vascular disease."

    The TCAR system gained U.S. Food and Drug Administration approval in 2015 and is supported by several clinical studies demonstrating a reduced risk of stroke and other complications associated with traditional open surgery. The products sold by Silk Road Medical are the only devices commercially available for use during the TCAR procedure.

    Boston Scientific expects to complete the transaction in the second half of 2024, subject to customary closing conditions. Silk Road Medical has guided to net revenue of approximately $194-198 million in 2024, representing 10-12% growth over the prior fiscal year.iii The impact to Boston Scientific adjusted earnings per share is expected to be immaterial in 2024 and 2025, and accretive thereafter. We expect the impact to GAAP earnings per share to be less accretive, or dilutive, as the case may be, due to amortization expense and acquisition-related net charges.

    About Boston Scientific

    Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding financial and business impact of the transaction and anticipated benefits of the transaction, the closing of the transaction and the timing thereof, business plans and strategy, product launches and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forward-looking statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

    Risks and uncertainties that may cause such differences include, among other things: economic,  political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; demographic trends; the closing and integration of acquisitions, including our ability to achieve the anticipated benefits of the proposed transaction and successfully integrate Silk Road Medical's operations; business disruptions (including disruptions in relationships with employees, customers and suppliers) following the announcement and/or closing of the proposed transaction; intellectual property rights; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives;  future business decisions made by us and our competitors; the conditions to the completion of the proposed transaction, including receipt of the required regulatory approvals and clearances, may not be satisfied at all or in a timely manner; and the closing of the proposed transaction may not occur or may be delayed. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"), which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.

    CONTACTS:

    Blake Rouhani

    Media Relations

    (763) 494-2268

    [email protected]

    Jon Monson

    Investor Relations

    (508) 683-5450

    [email protected]

    i Enterprise value of approximately $1.16 billion based on approximately 46.0 million fully diluted shares (or approximately $1.26 billion for 100% of the equity) and $101 million net cash position as of March 31, 2024

    ii Weerd M Stroke 2010; Modus Health Group for 2022

    Vascularweb.org; Virani, Salim, et al. "Heart Disease and Stroke Statistics— 2020 Update." American Heart Association, 3 Mar. 2020.

    iii https://investors.silkroadmed.com/news-releases/news-release-details/silk-road-medical-reports-first-quarter-2024-financial-results#:~:text=Silk%20Road%20Medical%20projects%20revenue,the%20Company's%20prior%20year%20revenue.

     

    Cision View original content:https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-silk-road-medical-inc-302175421.html

    SOURCE Boston Scientific Corporation

    Get the next $BSX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BSX
    $SILK

    CompanyDatePrice TargetRatingAnalyst
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    Boston Scientific Corporation
    $BSX
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    Boston Scientific Corporation
    $BSX
    10/18/2024Buy → Hold
    Needham
    Silk Road Medical Inc.
    $SILK
    7/11/2024Buy → Sell
    Argus
    Boston Scientific Corporation
    $BSX
    5/30/2024$90.00Buy
    Goldman
    Silk Road Medical Inc.
    $SILK
    3/7/2024$24.00Hold → Buy
    Argus
    Boston Scientific Corporation
    $BSX
    2/1/2024$65.00 → $80.00Neutral → Buy
    Mizuho
    More analyst ratings

    $BSX
    $SILK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System

      The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for the system in the treatment of drug refractory, symptomatic persistent atrial fibrillation (AF), an arrythmia in which the heart beats abnormally for at least seven days.

      7/7/25 7:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces conference call discussing second quarter 2025 results

      MARLBOROUGH, Mass., July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 23 prior to the conference call. A live webcast and replay for the eve

      7/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    SEC Filings

    See more
    • SEC Form 11-K filed by Boston Scientific Corporation

      11-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      6/18/25 5:14:10 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Corporation filed SEC Form 8-K: Other Events

      8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      5/28/25 7:45:47 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Boston Scientific Corporation

      SD - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

      5/22/25 4:10:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Boston Scientific with a new price target

      Leerink Partners initiated coverage of Boston Scientific with a rating of Outperform and set a new price target of $118.00

      6/16/25 7:46:14 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific upgraded by Needham with a new price target

      Needham upgraded Boston Scientific from Hold to Buy and set a new price target of $113.00

      4/16/25 9:01:10 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Boston Scientific from Hold to Buy and set a new price target of $108.00

      1/10/25 8:51:50 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Group Pres, Cardiology Fitzgerald Joseph Michael bought $4,515 worth of shares (50 units at $90.29), sold $1,799 worth of shares (20 units at $89.97), was granted 31,680 shares and covered exercise/tax liability with 14,447 shares, increasing direct ownership by 17% to 172,863 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      2/13/25 4:32:41 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Ballinger Kevin J. bought $198,783 worth of shares (11,700 units at $16.99), increasing direct ownership by 192% to 17,807 units (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      3/7/24 6:01:30 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP and CFO Monson Jonathan

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:43 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • EVP & Group Pres, Cardiology Fitzgerald Joseph Michael exercised 50,000 shares at a strike of $26.15 and sold $5,348,315 worth of shares (50,000 units at $106.97) (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:41 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • SVP, GC and Corp. Secretary Brown Vance R converted options into 4,036 shares and covered exercise/tax liability with 1,952 shares, increasing direct ownership by 7% to 33,451 units (SEC Form 4)

      4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

      7/2/25 4:09:38 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 1, 2024 - FDA Roundup: March 1, 2024

      For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

      3/1/24 4:00:21 PM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Leadership Updates

    Live Leadership Updates

    See more
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

      Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

      4/3/25 11:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner

      BEIJING and IRVINE, Calif., Jan. 6, 2025 /PRNewswire/ -- Sherpa Healthcare Partners, a global healthcare venture capital firm focused on early and growth stage healthcare companies primarily in Asia and the United States, announced today the appointment of Raymond W. Cohen as Venture Partner. Mr. Cohen is a seasoned healthcare executive and until recently, served as the CEO and member of the board of directors of Axonics, Inc., an Irvine, California-based global medical technology company that Cohen co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1

      1/6/25 9:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.

      SC 13D/A - Silk Road Medical Inc (0001397702) (Subject)

      9/19/24 8:16:37 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Silk Road Medical Inc.

      SC 13D - Silk Road Medical Inc (0001397702) (Subject)

      8/12/24 4:21:48 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silk Road Medical Inc.

      SC 13G/A - Silk Road Medical Inc (0001397702) (Subject)

      7/10/24 1:45:37 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $BSX
    $SILK
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific announces conference call discussing second quarter 2025 results

      MARLBOROUGH, Mass., July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 23 prior to the conference call. A live webcast and replay for the eve

      7/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces results for first quarter 2025

      MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.56 a year ago.

      4/23/25 6:30:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care
    • Boston Scientific announces conference call discussing first quarter 2025 results

      MARLBOROUGH, Mass., April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2025, on Wednesday, April 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 23 prior to the conference call. A live webcast and replay for the

      4/1/25 8:00:00 AM ET
      $BSX
      Medical/Dental Instruments
      Health Care